A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...
Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...
This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...
